CVE-2018-14787
In Philips' IntelliSpace Cardiovascular (ISCV) products (ISCV Version 2.x or prior and Xcelera Version 4.1 or prior), an attacker with escalated privileges could access folders which contain executables where authenticated users have write permissions,…
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (0.39%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
In Philips' IntelliSpace Cardiovascular (ISCV) products (ISCV Version 2.x or prior and Xcelera Version 4.1 or prior), an attacker with escalated privileges could access folders which contain executables where authenticated users have write permissions, and could then execute arbitrary code with local administrative permissions.
- CVSS 3.1
- 7.8 HIGHCVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
- EPSS
- 0.39% probability · 33th percentile
- Public exploits
- None in Exploit-DB
- CISA KEV
- Not listed
- Weakness
- CWE-269
- Affected
- philips/intellispace cardiovascular · philips/xcelera
- Source
- ics-cert@hq.dhs.gov
EPSS 0.4% since 27 October 2026; no change recorded yet. Points are recorded when the score first appears and whenever it moves by a percentage point or more.
References
- https://ics-cert.us-cert.gov/advisories/ICSMA-18-226-01Third Party Advisory, US Government Resource
- https://www.usa.philips.com/healthcare/about/customer-support/product-securityVendor Advisory
- https://ics-cert.us-cert.gov/advisories/ICSMA-18-226-01Third Party Advisory, US Government Resource
- https://www.usa.philips.com/healthcare/about/customer-support/product-securityVendor Advisory
Source: NVD record, EPSS from FIRST.org, KEV from CISA, exploits from Exploit-DB. Refreshed daily. Download this record as JSON.